Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation
Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation
复制标题
老龄化社会中复发性膀胱癌：主要组织相容性复合物 I 类抗原呈递的重要性
DOI：
10.1002/ijc.33359
复制
发表时间：
2020-10
影响因子：
6.4
通讯作者：
Malgorzata A.Garstka
中科院分区：
文献类型：
--
作者：
Edyta Wieczorek;Malgorzata A.Garstka
衰老与免疫反应不足有关，免疫反应不足可能导致各种恶性肿瘤的发生和发展。膀胱癌（BC）常见于老年患者，主要表现为复发性非肌肉浸润性BC，需要进一步治疗。人们对活化患者的免疫细胞非常感兴趣，重点是CD8+ T细胞。成功的治疗还应确保主要组织相容性复合体（MHC） I类分子有效地呈递BC抗原。本系统综述的目的是介绍MHC I类在BC研究和治疗中的作用的现有文献。在文献数据库PubMed和Web of Science中检索了2009年1月至2020年9月期间发表的关于MHC I类与BC关系的文章。我们检索了MHC I类及其在BC、衰老和MHC I类在BC免疫治疗中的重要性的相关出版物。基于现有的证据，我们提出MHC I类表达的缺失可能导致BC在经尿道切除后复发，并且对卡介苗芽孢杆菌免疫治疗无反应。我们讨论了在BC治疗中增强MHC I类抗原向CD8+ T细胞呈递的不同方法。以MHC I类表达模式和肿瘤浸润免疫细胞为特征的免疫状态可能提供有价值的预后信息，说明哪些患者可能从经尿道BC切除术和额外的免疫治疗中获益。
Aging is associated with an insufficient immune response that may lead to the initiation and progression of various malignancies. Bladder cancer (BC), prevalent in elderly patients, predominantly presents as recurrent nonmuscle invasive BC that requires further treatment. There is much interest in the activation of patients' immune cells with the focus on CD8+ T cells. Successful therapy should also ensure the efficient presentation of BC antigens by major histocompatibility complex (MHC) class I molecules. The purpose of this systematic review is to present the existing literature on the role of MHC class I in BC research and therapy. The bibliographic databases PubMed and Web of Science were searched for articles published between January 2009 and September 2020 that addressed MHC class I relationship to BC. We searched for available relevant publications on MHC class I and its role and regulation in BC, aging and MHC class I importance in BC immunotherapy. Based on the provided evidence, we propose that the loss of MHC class I expression in BC may lead to its recurrence after the transurethral resection and unresponsiveness to Bacillus Calmette‐Guerin immunotherapy. We discuss different ways to enhance MHC class I antigen presentation to CD8+ T cells in BC treatment. The immune status characterized by MHC class I expression patterns and cancer‐infiltrating immune cells may provide valuable prognostic information about which patients may benefit from transurethral resection of BC and additional immunotherapy.
登录
查看更多内容
DOI：
10.1016/s0022-5347(08)61084-8
发表时间：
2008-04
期刊：
The Journal of Urology
影响因子：
--
作者：
T. Yuasa;Kiyoshi Sato;N. Tsuchiya;S. Kimura;E. Ashihara;T. Maekawa;T. Habuchi
通讯作者：
T. Yuasa;Kiyoshi Sato;N. Tsuchiya;S. Kimura;E. Ashihara;T. Maekawa;T. Habuchi
DOI：
10.1073/pnas.1222342110
发表时间：
2013-02-26
影响因子：
11.1
作者：
Boyle, Louise H.;Hermann, Clemens;Trowsdale, John
通讯作者：
Trowsdale, John
DOI：
10.1016/j.urolonc.2005.11.026
发表时间：
2006-07-01
影响因子：
2.7
作者：
Joudi, Fadi N.;Smith, Brian J.;O'Donnell, Michael A.
通讯作者：
O'Donnell, Michael A.
DOI：
10.1007/s00262-018-2197-x
发表时间：
2018-07
期刊：
Cancer Immunology, Immunotherapy
影响因子：
--
作者：
W. Obara;I. Hara;Y. Kato;Renpei Kato;Keiji Inoue;F. Sato;H. Mimata;Yusuke Nakamura;T. Fujioka-T.-Fujio
通讯作者：
W. Obara;I. Hara;Y. Kato;Renpei Kato;Keiji Inoue;F. Sato;H. Mimata;Yusuke Nakamura;T. Fujioka-T.-Fujio
影响因子：
5.4
作者：
Wherry, EJ;Blattman, JN;Ahmed, R
通讯作者：
Ahmed, R